Genentech attempts to keep Avastin's breast cancer indication

08/7/2011 | Genetic Engineering & Biotechnology News

In a post-hearing document, Genentech asked the FDA to retain Avastin's breast cancer approval by allowing an updated label as well as a risk evaluation and mitigation strategy and a medication guide. The company also reiterated its plan to undertake a confirmatory study of Avastin plus chemotherapy drug paclitaxel for HER2-negative metastatic breast cancer.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ